Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) EBIT (2016 - 2026)

Usana Health Sciences (USNA) has disclosed EBIT for 16 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 92.15% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $41.8 million, a 49.2% decrease, with the full-year FY2024 number at $66.3 million, down 28.74% from a year prior.
  • EBIT was $1.2 million for Q3 2025 at Usana Health Sciences, down from $16.7 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $157.0 million in Q4 2021 to a low of -$31.1 million in Q4 2022.
  • A 5-year average of $28.8 million and a median of $24.2 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: soared 246.14% in 2021, then crashed 167.2% in 2022.
  • Usana Health Sciences' EBIT stood at $157.0 million in 2021, then plummeted by 119.79% to -$31.1 million in 2022, then soared by 177.94% to $24.2 million in 2023, then crashed by 66.1% to $8.2 million in 2024, then plummeted by 85.09% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's EBIT are $1.2 million (Q3 2025), $16.7 million (Q2 2025), and $15.7 million (Q1 2025).